Triptans: Low utilization and high turnover in the general population

Cephalalgia

Volumn 30, Issue 5, 2010, Pages 576-581

  Panconesi, A ^a   Pavone, E ^a   Franchini, M ^a   Mennuti, N ^a   Bartolozzi, M L ^a   Guidi, L ^a   Banfi, R ^a  

^a Health Authority 11   (Italy)

Author keywords

Migraine; Prescription data; Triptan discontinuation; Triptans; Turnover

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ARTICLE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; HUMAN; ITALY; MAJOR CLINICAL STUDY; MIGRAINE; PRESCRIPTION;

ADOLESCENT; ADULT; AGED; DRUG UTILIZATION; HUMANS; ITALY; MIDDLE AGED; MIGRAINE DISORDERS; PATIENT COMPLIANCE; TRYPTAMINES; YOUNG ADULT;

EID: 77956238052     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2009.02001.x     Document Type: Article

References (32)

1. Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher AI, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210.
2. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75.
3. Lainez MJA, Galvan J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol 2007;14:269-75.
4. Dowson AJ, Tepper SJ, Dahlof C. Patients' preference for triptans and other medication as a tool for assessing the efficacy of acute treatments for migraine. J Headache Pain 2005;6:112-20.
5. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global migraine and zolmitriptan evaluation survey. Headache 2003;43:19-26.
6. Panconesi A, Pavone E, Vacca F, Vaiani M, Banfi R. Triptans in the Italian population: a drug utilization study and a literature review. J Headache Pain 2008;9:71-6.
7. Pavone E, Banfi R, Vaiani M, Panconesi A. Patterns of triptans use: a study based on the records of a community pharmaceutical department. Cephalalgia 2007;27:1000-4.
8. Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication-a review. Cephalalgia 2004;24:321-32.
9. Dodick DW. Triptan nonresponder studies: implication for clinical practice. Headache 2005;45:156-62.
10. Dahlof CGH. Infrequent or non-response to oral sumatriptan does not predict response to other triptans-review of four trials. Cephalalgia 2006;26:98-106.
11. Visser WH, de Vriend RHM, Jaspers NHWM, Ferrari MD. Sumatriptan- nonresponders: a survey in 366 migraine patients. Headache 1996;36:471-5.
12. Burnstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004;55:19-26.
13. Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H, et al. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind placebo-controlled trial of almotriptan. Cephalalgia 2008;28:383-91.
14. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 2001;10:1831-45.
15. Diener H-C, Dodick DW, Goadsby PJ, Lipton RB, Almas M, Parsons B. Identification of negative predictors of pain-free response to triptans: analysis of the eletriptan database. Cephalalgia 2008;28:35-40.
16. Gaist D. Use and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data. Cephalalgia 1999;19:735-61.
17. Sondergaard J, Foged A, Kragstrup J, Gaist D, Gram LF, Sindrup SH, et al. Intensive community pharmacy intervention had little impact on triptan consumption: a randomized controlled trial. Scand J Prim Health Care 2006;24:16-21.
18. Rahimtoola H, Egberts ACG, Buurma H, Tijssen CC, Leufkens HG. Patterns of ergotamine and sumatriptan use in the Netherlands from 1991 to 1997. Cephalalgia 2001;21:596-603.
19. Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache 2007;47:475-9.
20. Lugardon S, Roussel H, Sciortino V, Montastruc JL, Lapeyre-Mestre M. Triptan use and risk of cardiovascular events: anested-case-control study from the French health system database. Eur J Clin Pharmacol 2007;63:801-7.
21. Etemad LR, Yang W, Globe D, Barlev A, Johnson KA. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm 2005;11:137-44.
22. Ifergane G, Wirguin I, Shvartzman P. Triptans-why once? Headache 2006;46:1261-3.
23. Lohman JJHM, van der Kuy-de Ree MM. Patterns of specific antimigraine drug use-a study based on the records of 18 community pharmacies. Cephalalgia 2005;25:214-18.
24. Savani N, Martin A, Browning D. Switching patients with migraine from sumatriptan to other triptans increases primary care costs. Int J Clin Pract 2004;58:758-63.
25. Walling A, Woolley DC, Molgaard C, Kallail KJ. Do family physicians fail to provide triptans for patients with migraine? J Fam Practice 2006;55:1057-62.
26. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts ACG. Single use of sumatriptan: a patient interview study. Headache 2003;43:109-16.
27. Ferrari A, Pasciullo G, Savino G, Cicero A, Ottani A, Bertolini A, et al. Headache treatment before and after the consultation of a specialized centre: a pharmacoepidemiology study. Cephalalgia 2004;24:356-62.
28. De Diego EV, Lanteri-Minet M. Recognition and management of migraine in primary care: influence of functional impact measured by the headache impact test (HIT). Cephalalgia 2005;25:184-90.
29. Lygberg AC, Rasmussen BK, Jorgensen T, Jensen R. Prognosis of migraine and tension-type headache: a population-based follow-up study. Neurology 2005;65:580-5.
30. Tfelt-Hansen P. Triptans vs other drugs for acute migraine. Are there differences in efficacy? A comment. Headache 2008;48:601-5.
31. Mett A, Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr Opin Neurol 2008;21:331-7.
32. Goldstein J, Silberstein SD, Saper JR, Elkind AH, Smith TR, Gallagher RM, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine. Headache 2005;45:973-82.